



CT

1600

0800

09264732

Patent SF0896K

TECH CENTER 1600/2900

OCT 30 2001

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
VICARI, *et al.*

Group Art. Unit: (To Be Assigned)

For Patent: **CHEMOKINES AS
ADJUVANTS OF IMMUNE RESPONSE**

Examiner: (To Be Assigned)

Serial No.: 09/768,917

Filed: January 24, 2001

Date: September 25, 2001

Schering-Plough Corporation
Kenilworth, New Jersey 07033-0530

Assistant Commissioner for Patents
Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants respectfully request that the following documents, as listed below and on the accompanying PTO-1449 Form be considered and made of record. The Examiner is kindly requested to initial and return the PTO-1449 Form to evidence consideration of these references:

1. Youseff, S. *et al.*, 2000, "CC-Chemokine-Encoding DNA Vaccines Enhance Break down of Tolerance to their Gene Products and Treat Ongoing Adjuvant Arthritis" *J. Clin. Invest.* **106**:361-371
2. Xin, K.Q. *et al.*, 1999, "Immunization of RANTES Expression Plasmid with a DNA Vaccine Enhances HIV-1 Specific Immunity" *Clin. Immunol.* **92**:90-96.
3. Sin, J. *et al.*, 2000, "DNA Vaccines Encoding Interleukin-8 and RANTES Enhance Antigen-Specific Th1-type (CD4(+)) T-cell-mediated Protective Immunity against Herpes Simplex Virus Type 2 in Vivo." *J. Virol.* **74**:11173-11180.

4. Nomura, T. *et al.*, 2000, "Chemokines and Anti-cancer Immunotherapy" *Anticancer Res.* **20**:4073-4080.
5. Lu, Y. *et al.*, 1999, "Macrophage Inflammatory Protein 1 Alpha Expression Plasmid enhances DNA Vaccine-Induced Immune Response Against HIV-1" *Clin Exp. Immunol.* **115**:335-341.
6. Lillard, J.W. *et al.*, 1999, "Lymphotactin acts as an Innate Mucosal Adjuvant" *J. Immunol.* **162**:1959-1965.
7. Lehner, T. *et al.*, 2000, "Heat Shock Proteins Generate Beta-Chemokines which Function as innate adjuvants enhancing Adaptive Immunity" *Eur. J. Immunol.* **30**:594-603.
8. Laning, J. *et al.*, 1994, "Inhibition of in Vivo Tumor Growth by the Beta Chemokine, TCA3" *J. Immunol.* **153**:4625-4635.
9. Kim, J.J. *et al.*, 2000, "Chemokine Gene Adjuvants can Modulate Immune Responses Induced by DNA Vaccines" *J. Interferon Cytokine Res.* **20**:487-498.
10. Braun, S.E. *et al.*, 2000, "The CC Chemokine CK Beta-11/MIP-3 beta/ELC/Exodus 3 Mediates Tumor Rejection of Murine Breast Cancer Cells through NK Cells" *J. Immunol.* **164**:4025-4031.
11. Biragyn, A. *et al.*, "Genetic Fusion of Chemokines to Self Tumor Antigen Induces Protective, T-Cell dependent Antitumor Immunity" *Nat. Biotechnol.* **17**:253-258.

Applicants' submission of this Supplemental Information Disclosure Statement is not an admission that any reference cited herein qualifies as prior art.

The Commissioner is authorized to charge any fees in order to enter this Supplemental Information Disclosure to Deposit Account No. 19-0365.

Respectfully submitted,



Jaye McLaughlin
Attorney/Agent for Applicant(s)
Registration No.: 41,211
Telephone No.: (908) 298-4299

SCHERING-PLOUGH CORPORATION
Patent Department, K-6-1, 1990
2000 Galloping Hill Road
Kenilworth, New Jersey 07033-0530
Date: September 25, 2001

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on

September 25, 2001
Date of Deposit

Jaye McLaughlin
Registered Representative


Signature & Date

18880_1